Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06905288
Recruiting Observational

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

NCT06905288 · tracked via the Priya Life Science South Korea tracker
Sponsor
Novartis Pharmaceuticals
Phase
Observational
Started
2025-04-02
Last updated
2026-08-18

Condition(s) studied

Ankylosing Spondylitis

Investigational drug(s) / intervention(s)

Secukinumab →

Secukinumab: This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Study summary

This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria 2. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4 3. Subjects who have never used TNFi, JAKi, or IL-17i drugs before 4. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety 5. Subjects who have a time of less than 5 years since AS diagnosis 6. Subjects who are above the age of 18 years and below 40years old 7. Subjects who give informed consent form to participate in the study Exclusion Criteria: 1. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks) 2. Subjects who have congenital/traumatic spinal deformities 3. Subjects currently enrolled in other clinical studies 4. Subjects who have any contraindications to secukinumab treatment

Primary outcome measure(s)

  • Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) — Baseline and 28 weeks
    The BASDAI consists of 6 questions to measure the participant's symptoms and disease activity, and each question is evaluated using a numeric rating scale from 0 to 10 or a 10 cm Visual Analog Scale (VAS) with 0 being no problem and 10 being the worst problem

Trial sites (3)

FacilityCityRegionStatus
Novartis Investigative Site Jinju Gyeongsangnam-do Recruiting
Novartis Investigative Site Busan South Korea Recruiting
Novartis Investigative Site Gwangju South Korea Recruiting

On this site

📄 Cosentyx (secukinumab) drug profile →

More Novartis Pharmaceuticals trials in South Korea

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Active, not recruiting
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea Recruiting
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) Active, not recruiting

Other trials for the same condition

Multi-omics Database for Integrative Microbiome Analysis in a Cohort of Korean Patients With Ankylosing Spondylitis Recruiting
Korean College of Rheumatology Biologics and Targeted Therapy Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06905288 on ClinicalTrials.gov ↗ ← All trials in South Korea